Country Club Trust Company N.a. buys $9,704,919 stake in Pfizer (PFE)

Pfizer (PFE) : Country Club Trust Company N.a. scooped up 2,311 additional shares in Pfizer during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 14, 2016. The investment management firm now holds a total of 297,150 shares of Pfizer which is valued at $9,704,919.Pfizer makes up approximately 1.40% of Country Club Trust Company N.a.’s portfolio.

Other Hedge Funds, Including , Btr Capital Management Inc boosted its stake in PFE in the latest quarter, The investment management firm added 86,117 additional shares and now holds a total of 236,560 shares of Pfizer which is valued at $7,726,050. Pfizer makes up approx 1.76% of Btr Capital Management Inc’s portfolio.Canandaigua National Bank Trust Co boosted its stake in PFE in the latest quarter, The investment management firm added 2,127 additional shares and now holds a total of 167,953 shares of Pfizer which is valued at $5,564,283. Pfizer makes up approx 1.65% of Canandaigua National Bank Trust Co’s portfolio.Banced Corp boosted its stake in PFE in the latest quarter, The investment management firm added 16,141 additional shares and now holds a total of 25,687 shares of Pfizer which is valued at $851,010. Pfizer makes up approx 1.69% of Banced Corp’s portfolio.Creative Planning boosted its stake in PFE in the latest quarter, The investment management firm added 67,080 additional shares and now holds a total of 740,302 shares of Pfizer which is valued at $24,526,205. Pfizer makes up approx 0.16% of Creative Planning’s portfolio.Bath Savings Trust Co boosted its stake in PFE in the latest quarter, The investment management firm added 1,054 additional shares and now holds a total of 18,081 shares of Pfizer which is valued at $612,946. Pfizer makes up approx 0.19% of Bath Savings Trust Co’s portfolio.

Pfizer closed down -0.1 points or -0.31% at $32.66 with 1,55,69,339 shares getting traded on Friday. Post opening the session at $32.73, the shares hit an intraday low of $32.66 and an intraday high of $32.9 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, Pfizer reported $0.64 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Aug 2, 2016. Analyst had a consensus of $0.62. The company had revenue of $13147.00 million for the quarter, compared to analysts expectations of $13013.24 million. The company’s revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.56 EPS.

Investors should note that on Sep 22, 2016, Pfizer announced a cash dividend of $0.3000. The company’s management has announced Nov 9, 2016 as the ex-dividend date and fixed the record date on Nov 11, 2016. The payable date has been fixed on Dec 1, 2016.

Many Wall Street Analysts have commented on Pfizer. Pfizer was Downgraded by Jefferies to ” Hold” on Oct 13, 2016.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Pfizer - Is it time to Sell?

Top Brokerage Firms are advising their investors on Pfizer. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.